Supportive Care in Extensive-Stage Small Cell Lung Cancer: Optimizing Myeloprotection Through Multidisciplinary Practice

This OncLive® Insights program examines the evolving role of supportive care in extensive-stage small cell lung cancer (ES-SCLC), with a focus on the clinical burden of chemotherapy-induced myelosuppression (CIM) and its impact on treatment delivery, patient outcomes, and quality of life. Megan May, PharmD, moderates a multidisciplinary discussion with Taylor Praska, PharmD, and Amanda Edmond, PA-C, who explore the challenges associated with hematologic toxicities and the limitations of traditional reactive supportive care approaches. The panel discusses the scientific rationale for proactive myeloprotection, including the mechanism of action and clinical evidence supporting trilaciclib, while reviewing its potential role in preserving bone marrow function during platinum-etoposide-containing chemotherapy. Practical insights are shared on patient selection, treatment planning, workflow integration, multidisciplinary collaboration, and patient education, alongside emerging real-world evidence evaluating hospitalization rates, healthcare resource utilization, and quality-of-life outcomes. Throughout the discussion, the faculty emphasize individualized supportive care strategies that help maintain treatment continuity, minimize chemotherapy-related complications, and optimize the overall care experience for patients with ES-SCLC.